X-ray equipment manufacturer Fischer Imaging experienced recordrevenues and improved earnings in the third quarter (end-October). The Denver company's revenues totaled $19.1 million, a jump of23% from third-quarter results a year ago, when Fischer had
X-ray equipment manufacturer Fischer Imaging experienced recordrevenues and improved earnings in the third quarter (end-October).
The Denver company's revenues totaled $19.1 million, a jump of23% from third-quarter results a year ago, when Fischer had salesof $15.5 million. The company reported earnings of $883,000 comparedto a loss of $4.7 million in the third quarter of 1994. Earningsadjustments last year included a $4.3 million write-down for adiscontinued product and other nonrecurring costs, according tothe company.
"Strong third-quarter results confirm our belief that effortsto reduce costs and improve our sales mix are taking hold,"said Morgan Nields, chairman and CEO.
The results occurred despite start-up costs relating to a newtilt-table interventional C-arm system and a 24% increase in R&Dspending, Nields noted.
Emerging PET/CT Agent Shows Promise in Detecting PCa Recurrence in Patients with Low PSA Levels
February 13th 202518F-DCFPyL facilitated detection of recurrent prostate cancer in 51 percent of patients with PSA levels ranging between 0.2 to 0.5 ng/ml, according to new research presented at the American Society of Clinical Oncology Genitourinary Cancers (ASCO-GU) Symposium.
Emerging MRI Scoring System May Help Predict Recurrent and Metastatic Hepatocellular Carcinoma
February 12th 2025Preoperative use of the scoring system for gadoxetic acid-enhanced MRI demonstrated an average AUC of 85 percent and average specificity of 89 percent in external validation cohorts for pathologic features of hepatocellular carcinoma.
Key Chest CT Parameters for Body Composition May be Prognostic for Patients with Resectable NSCLC
February 11th 2025A high intermuscular adipose index has a 49 percent increased likelihood of being associated with lower overall survival in patients with resectable non-small cell lung cancer (NSCLC), according to new research.